

Approved



**Asia Regional Program
Country Operational Plan
FY 2016**



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
USAID		0	4,453,406	4,453,406	1,780,390	6,233,796
DOD		0		0	71,408	71,408
HHS/CDC	4,116,875	6,007,921		10,124,796	0	10,124,796
HHS/HRSA		100,000		100,000	0	100,000
Total	4,116,875	6,107,921	4,453,406	14,678,202	1,851,798	16,530,000

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency				On Hold Amount	Total
	DOD	HHS/CDC	HHS/HRSA	USAID		
HBHC		922,712	50,000	674,073	0	1,646,785
HLAB	0	720,244			0	720,244
HMBL	0				0	0
HTXS		751,599		1,003,303	0	1,754,902
HVCT	0	969,813		962,119	0	1,931,932
HVMS	0	2,933,848		507,074	0	3,440,922
HVOP	0	1,084,624	50,000	828,973	0	1,963,597
HVSI	0	1,417,700		31,996	0	1,449,696
HVTB		115,768			0	115,768
IDUP		5,272			0	5,272
MTCT		23,460			0	23,460
OHSS	0	1,065,383		445,868	0	1,511,251
PDCS		70,876			0	70,876
PDTX		43,497			0	43,497

Approved



	0	10,124,796	100,000	4,453,406	0	14,678,202
--	---	------------	---------	-----------	---	------------



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	1,180,675	0
HVTB	17,403	0
PDCS	34,881	0
Total Technical Area Planned Funding:	1,232,959	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	322,616	0
HVSI	669,381	0
OHSS	967,629	0
Total Technical Area Planned Funding:	1,959,626	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HMBL	0	
HVCT	1,369,635	0
HVOP	1,412,816	0
IDUP	0	
MTCT	5,000	0
Total Technical Area Planned Funding:	2,787,451	0

Technical Area: Treatment

Approved



Budget Code	Budget Code Planned Amount	On Hold Amount
HTXS	1,375,085	0
PDTX	22,400	0
Total Technical Area Planned Funding:	1,397,485	0



Technical Area Summary Indicators and Targets

China

Indicator Number	Label	2017
KP_PREV_TA	KP_PREV_TA Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (TA-only)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	20,371
	Total estimated number of key population in the catchment area	138,571
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are	



	based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men and are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men and are NOT sex workers (Numerator: Number of key populations reached with	20,371



	individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men and are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	138,571
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type:	



	Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known positive	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: Returning beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,618
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	



	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	



	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	18
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	834
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	24
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	742
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	0



	Test Result by Aggregated Age and Sex: Positive 15+ Male	398
	Test Result by Aggregated Age and Sex: Positive <15 Female	5
	Test Result by Aggregated Age and Sex: Positive 15+ Female	196
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	635
	Service Delivery Point (Community): Homebased testing	0
	Service Delivery Point (Community): Mobile testing	0
	Service Delivery Point (Community): Other	933
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	



	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility): Outpatient	
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	
	Service Delivery Point (Facility): VCT	35
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	15
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	



	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
	HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months
Age/sex: 5-9 Male		
Age/sex: 10-14 Male		
Age/sex: 15-19 Male		
Age/sex: 20-24 Male		



	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	



	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	11,900
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	



	Test Result by Aggregated Age and Sex: Positive <15 Male	
	Test Result by Aggregated Age and Sex: Positive 15+ Male	962
	Test Result by Aggregated Age and Sex: Positive <15 Female	
	Test Result by Aggregated Age and Sex: Positive 15+ Female	
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	11,900
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	



	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility): Outpatient	
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	
	Service Delivery Point (Facility): VCT	
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	



	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	390
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	



	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	1
	Aggregated Age/Sex: 15+ Male	219
	Aggregated Age/Sex: <15 Female	0
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	170
	Sum of Aggregated Age/Sex <15	1
	Sum of Aggregated Age/Sex 15+	389
	Sum of Aggregated Age/Sex disaggregates	390
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	60
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	



	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	0
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	42
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	0
	Aggregated Grouping by Age/Sex: 15+ Female	18
	Sum of Aggregated Age/Sex disaggregates	60
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12	n/a



	months with a suppressed viral load (<1000 copies/ml)	
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	268
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	287
	Numerator: Indication: Routine	268
	Numerator: Indication: Targeted	0
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication:	



	25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication:	



	25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	287
	Denominator: Indication: Targeted	0
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by	



	Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by	



	Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	1
	Numerator Aggregated Age/Sex: 15+ Male	144
	Numerator Aggregated Age/Sex: <15 Female	0
	Numerator Aggregated Age/Sex: 15+ Female	123
	Denominator Aggregated Age/Sex:	1



	<15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	154
	Denominator Aggregated Age/Sex: <15 Female	0
	Denominator Aggregated Age/Sex: 15+ Female	132
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	295
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	330
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who	



	are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 50+ Female (Numerator:	



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated	



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	



	those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated	



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	156
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Aggregated Age/Sex: 15+ Female	138



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	177
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	152

Approved





Technical Area Summary Indicators and Targets

Laos

Indicator Number	Label	2017
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	4,020
	Total estimated number of key population in the catchment area	
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet	



	the minimum standards required)	
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key	



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key	



	population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,024
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	



	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex:	



	Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,024
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	
	Test Result by Aggregated Age	72



	and Sex: Positive 15+ Male	
	Test Result by Aggregated Age and Sex: Positive <15 Female	
	Test Result by Aggregated Age and Sex: Positive 15+ Female	
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility):	



	Inpatient	
	Service Delivery Point (Facility): Outpatient	
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	
	Service Delivery Point (Facility): VCT	
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by	



	Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,038
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	



	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex:	



	Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,038
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age	



	and Sex: Positive <15 Male	
	Test Result by Aggregated Age and Sex: Positive 15+ Male	32
	Test Result by Aggregated Age and Sex: Positive <15 Female	
	Test Result by Aggregated Age and Sex: Positive 15+ Female	
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community)	



	by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility): Outpatient	
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	
	Service Delivery Point (Facility): VCT	650
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by	



	Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
	TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)
Age/Sex: <1 Male		
Age/Sex: 1-4 Male		
Age/Sex: 5-14 Male		
Age/Sex: 15-19 Male		



	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	68
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	1,109
	Aggregated Age/Sex: <15 Female	74
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	1,042
	Sum of Aggregated Age/Sex <15	142
	Sum of Aggregated Age/Sex 15+	2,151
	Sum of Aggregated Age/Sex disaggregates	2,293
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_TA	Number of adults and children	617



	newly enrolled on antiretroviral therapy (ART)	
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	17
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	222
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex:	19



	<15 Female	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	290
	Sum of Aggregated Age/Sex disaggregates	548
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	977
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,026
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	



	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	



	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	977
	Numerator: Indication: Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	1,025
	Denominator: Indication: Targeted	



	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	



	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	



	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	25
	Numerator Aggregated Age/Sex: 15+ Male	472
	Numerator Aggregated Age/Sex: <15 Female	24
	Numerator Aggregated Age/Sex: 15+ Female	456
	Denominator Aggregated Age/Sex: <15 Male	26
	Denominator Aggregated Age/Sex: 15+ Male	495
	Denominator Aggregated Age/Sex: <15 Female	25
	Denominator Aggregated Age/Sex: 15+ Female	480
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	493
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	548
	Age/Sex: <1 (Numerator: Number	



	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on	



	treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	



	those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of	



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	



	those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on	15



	treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	200
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	261
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	17
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	222
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated	19



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	290
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
	CD4: Number of laboratories that participate in this PT program	4
	CD4: Number of laboratories that perform this testing	
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	Early infant diagnostics: Number of laboratories that participate in this PT program	
	Early infant diagnostics: Number of laboratories that perform this	



	testing	
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	53
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	70
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	HIV viral load: Number of laboratories that participate in this PT program	
	HIV viral load: Number of laboratories that perform this testing	
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	



	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	
	HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre
By Graduates: Doctors		
By Graduates: Nurses		
By Graduates: Midwives		
By Graduates: Social service workers		
By Graduates: Laboratory professionals		
By Graduates: Other		
Sum of Graduates disaggreagtes		

Technical Area Summary Indicators and Targets

Thailand

Indicator Number	Label	2017
KP_MAT_TA	KP_MAT_TA Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	6,976
	Sex: Female	698
	Sex: Male	6,278
	Sum of Sex Disaggregates	6,976
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have received antiretroviral preexposure	750
	Male 10-14	
	Male 15-19	
	Male 20-24	
	Male 25-49	
	Male 50+	
	Female 10-14	
	Female 15-19	
	Female 20-24	
	Female 25-49	
	Female 50+	



PrEP_NEW_TA	PrEP_NEW_TA Number of adult women and adolescent girls newly enrolled on oral or topical PrEP	n/a
	Number of adult women and adolescent girls newly enrolled on oral or topical PrEP	621
	Male 10-14	
	Male 15-19	
	Male 20-24	580
	Male 25-49	
	Male 50+	
	Female 10-14	
	Female 15-19	
	Female 20-24	41
	Female 25-49	
	Female 50+	
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	82,983
	Total estimated number of key population in the catchment area	
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with	



	<p>individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	



	<p>By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)</p>	
	<p>By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)</p>	
	<p>By key population type: Transgender who are sex workers</p>	



	(Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturning	



	beneficiary within the current report period	
KP_PREV_TA	KP_PREV_TA Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (TA-only)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,500
	Total estimated number of key population in the catchment area	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key	



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men and are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	289
	By key population type: Men who have sex with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,990
	By key population type:	



	Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	221
	By key population type: Men who have sex with men and are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in	



	prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known positive	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: Returning beneficiary within the current report period	
	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months
Age/sex: 5-9 Male		
Age/sex: 10-14 Male		
Age/sex: 15-19 Male		
Age/sex: 20-24 Male		
Age/sex: 25-49 Male		
Age/sex: 50+ Male		
Age/sex: 5-9 Female		
Age/sex: 10-14 Female		



	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	



	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	47,776
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	11,833
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	
	Test Result by Aggregated Age and Sex: Positive 15+ Male	6,924
	Test Result by Aggregated Age and Sex: Positive <15 Female	



	Test Result by Aggregated Age and Sex: Positive 15+ Female	938
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	26,755
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility): Outpatient	



	Service Delivery Point (Facility): Pediatric	40
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	
	Service Delivery Point (Facility): VCT	1,940
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	



	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	520
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	



	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	



	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	520
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	
	Test Result by Aggregated Age and Sex: Positive 15+ Male	92



	Test Result by Aggregated Age and Sex: Positive <15 Female	
	Test Result by Aggregated Age and Sex: Positive 15+ Female	
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	



	Service Delivery Point (Facility): Outpatient	
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	
	Service Delivery Point (Facility): VCT	520
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	



	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,900
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	
	Aggregated Age/Sex: 15+ Male	



	Aggregated Age/Sex: <15 Female	
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	
	Sum of Aggregated Age/Sex disaggregates	
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	6,625
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	



	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	3,377
	Aggregated Age/Sex: <15 Female	
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	3,248
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	6,625
	Sum of Aggregated Age/Sex disaggregates	6,625
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,284
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	



	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	
	Sum of Aggregated Age/Sex disaggregates	
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral	5,055



	therapy (ART)	
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	3,979
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	



	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	1,076
	Sum of Aggregated Age/Sex disaggregates	5,055
	Pregnancy status	
	Breastfeeding status	
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	12
	CD4: Number of laboratories that participate in this PT program	12
	CD4: Number of laboratories that perform this testing	
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	Early infant diagnostics: Number of laboratories that participate in this PT program	
	Early infant diagnostics: Number of laboratories that perform this testing	
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	42



	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	42
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	12
	HIV viral load: Number of laboratories that participate in this PT program	12
	HIV viral load: Number of laboratories that perform this testing	
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that	



	perform this testing	
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	230
	By Graduates: Doctors	
	By Graduates: Nurses	
	By Graduates: Midwives	
	By Graduates: Social service workers	
	By Graduates: Laboratory professionals	
	By Graduates: Other	
	Sum of Graduates disaggreagtes	



Technical Area Summary Indicators and Targets

Asia Regional Program

Indicator Number	Label	2017
KP_MAT_TA	KP_MAT_TA Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	6,976
	Sex: Female	698
	Sex: Male	6,278
	Sum of Sex Disaggregates	6,976
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have received antiretroviral preexposure	750
	Male 10-14	
	Male 15-19	
	Male 20-24	
	Male 25-49	
	Male 50+	
	Female 10-14	
	Female 15-19	
	Female 20-24	
	Female 25-49	
	Female 50+	



PrEP_NEW_TA	PrEP_NEW_TA Number of adult women and adolescent girls newly enrolled on oral or topical PrEP	n/a
	Number of adult women and adolescent girls newly enrolled on oral or topical PrEP	621
	Male 10-14	
	Male 15-19	
	Male 20-24	580
	Male 25-49	
	Male 50+	
	Female 10-14	
	Female 15-19	
	Female 20-24	41
	Female 25-49	
	Female 50+	
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	87,003
	Total estimated number of key population in the catchment area	
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with	



	<p>individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	



	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are sex workers	



	(Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturning	



	beneficiary within the current report period	
KP_PREV_TA	KP_PREV_TA Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (TA-only)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	22,871
	Total estimated number of key population in the catchment area	138,571
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key	



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men and are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	289
	By key population type: Men who have sex with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	22,361
	By key population type:	



	Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	221
	By key population type: Men who have sex with men and are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	138,571
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in	



	prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known positive	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: Returning beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	62,252
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
Age/sex: 10-14 Female		



	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	



	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	18
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	49,634
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	24
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	12,575
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	0
	Test Result by Aggregated Age and Sex: Positive 15+ Male	7,394
	Test Result by Aggregated Age and Sex: Positive <15 Female	5



	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,134
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	635
	Service Delivery Point (Community): Homebased testing	0
	Service Delivery Point (Community): Mobile testing	0
	Service Delivery Point (Community): Other	27,688
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility): Outpatient	



	Service Delivery Point (Facility): Pediatric	40
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	
	Service Delivery Point (Facility): VCT	1,975
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	15
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	



	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	15,458
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	



	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	



	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	15,458
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	
	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,086



	Test Result by Aggregated Age and Sex: Positive <15 Female	
	Test Result by Aggregated Age and Sex: Positive 15+ Female	
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	11,900
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	



	Service Delivery Point (Facility): Outpatient	
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	
	Service Delivery Point (Facility): VCT	1,170
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	



	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	4,290
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	1
	Aggregated Age/Sex: 15+ Male	219



	Aggregated Age/Sex: <15 Female	0
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	170
	Sum of Aggregated Age/Sex <15	1
	Sum of Aggregated Age/Sex 15+	389
	Sum of Aggregated Age/Sex disaggregates	390
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	9,020
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	



	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	68
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	4,486
	Aggregated Age/Sex: <15 Female	74
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	4,290
	Sum of Aggregated Age/Sex <15	142
	Sum of Aggregated Age/Sex 15+	8,776
	Sum of Aggregated Age/Sex disaggregates	8,918
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,344
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	



	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	0
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	42
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	0
	Aggregated Grouping by Age/Sex: 15+ Female	18
	Sum of Aggregated Age/Sex disaggregates	60
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral	5,672



	therapy (ART)	
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	17
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	4,201
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	19



	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	1,366
	Sum of Aggregated Age/Sex disaggregates	5,603
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	268
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	287
	Numerator: Indication: Routine	268
	Numerator: Indication: Targeted	0
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication:	



	Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication:	



	20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	287
	Denominator: Indication: Targeted	0
	Denominator: Preg/BF by	



	Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by	



	Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex	



	by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	1
	Numerator Aggregated Age/Sex: 15+ Male	144
	Numerator Aggregated Age/Sex: <15 Female	0
	Numerator Aggregated Age/Sex: 15+ Female	123
	Denominator Aggregated Age/Sex: <15 Male	1
	Denominator Aggregated Age/Sex: 15+ Male	154
	Denominator Aggregated Age/Sex: <15 Female	0
	Denominator Aggregated Age/Sex: 15+ Female	132
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	977
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical	1,026



	record and /or laboratory records in the past 12 months.	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	



	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	977
	Numerator: Indication: Targeted	



	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	1,025
	Denominator: Indication: Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	



	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	



	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	25
	Numerator Aggregated Age/Sex: 15+ Male	472
	Numerator Aggregated Age/Sex: <15 Female	24
	Numerator Aggregated Age/Sex: 15+ Female	456
	Denominator Aggregated Age/Sex: <15 Male	26
	Denominator Aggregated Age/Sex: 15+ Male	495
	Denominator Aggregated Age/Sex: <15 Female	25
	Denominator Aggregated Age/Sex: 15+ Female	480
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	295
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	330
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator:)	



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who	



	<p>initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and</p>	



	those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated	



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	



	those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	156
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	138
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1



	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	177
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	152
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	493
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	548



	stopped ART, and those lost to follow-up	
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	



	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated	



	<p>ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to</p>	



	follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated	



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	



	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	200
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	261
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	17
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	222



	<p>Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>19</p>
	<p>Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>290</p>
<p>LAB_PT_TA</p>	<p>Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program</p>	
	<p>CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program</p>	<p>15</p>
	<p>CD4: Number of laboratories that participate in this PT program</p>	<p>16</p>
	<p>CD4: Number of laboratories that perform this testing</p>	
	<p>Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program</p>	
	<p>Early infant diagnostics: Number of laboratories that participate in this PT program</p>	



	Early infant diagnostics: Number of laboratories that perform this testing	
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	95
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	112
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	12
	HIV viral load: Number of laboratories that participate in this PT program	12
	HIV viral load: Number of laboratories that perform this testing	
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that	



	achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	415
	By Graduates: Doctors	
	By Graduates: Nurses	
	By Graduates: Midwives	
	By Graduates: Social service workers	
	By Graduates: Laboratory professionals	
	By Graduates: Other	
	Sum of Graduates disaggreagtes	



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
16576	AIDS Care China	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	300,000
16622	Chinese Center for Disease Prevention and Control	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GAP, GHP-State	1,300,000
17035	TBD	TBD	Redacted	Redacted	Redacted
17084	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	0
17092	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	75,000
17309	FHI 360	NGO	U.S. Agency for International Development	GHP-USAID	3,727,521



17815	Research Triangle International	Private Contractor	U.S. Agency for International Development	GHP-USAID	0
17842	Health Research Inc./New York State Department of Health	Other USG Agency	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	50,000
17858	TBD	TBD	Redacted	Redacted	Redacted
17859	TBD	TBD	Redacted	Redacted	Redacted
17860	TBD	TBD	Redacted	Redacted	Redacted
18448	TBD	TBD	Redacted	Redacted	Redacted
18450	TBD	TBD	Redacted	Redacted	Redacted



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 16576	Mechanism Name: Engaging Local NGOs
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: AIDS Care China	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
China	0

Total All Funding Sources: 300,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 300,000		
Managing Country	Funding Source	Funding Amount
China	GHP-State	300,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	265,386
----------------------------	---------

Budget Code Information

Mechanism ID: 16576			
Mechanism Name: Engaging Local NGOs			
Prime Partner Name: AIDS Care China			
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	172,435	0
Governance and Systems	HVSI	42,639	0
Prevention	HVCT	18,979	0
Treatment	HTXS	65,947	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
China	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,618
China	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	18
China	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	834
China	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	24
China	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	742
China	HTC_TST_DSD	Sum of Aggregated Age/Sex <15	42
China	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,576
China	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,618
China	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	0
China	HTC_TST_DSD	Test Result by Aggregated Age and Sex:	398



		Positive 15+ Male	
China	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	5
China	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	196
China	HTC_TST_DSD	Service Delivery Point (Community): Index testing	635
China	HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	0
China	HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	0
China	HTC_TST_DSD	Service Delivery Point (Community): Other	933
China	HTC_TST_DSD	Service Delivery Point (Facility): VCT	35
China	HTC_TST_DSD	Service Delivery Point (Facility): Index testing	15
China	TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	390
China	TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1
China	TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	219
China	TX_CURR_DSD	Aggregated Age/Sex: <15 Female	0
China	TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	170
China	TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1
China	TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	389
China	TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	390
China	TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	60
China	TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0
China	TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	42
China	TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0
China	TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+	18



		Female	
China	TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	60
China	TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	268
China	TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	287
China	TX_PVLS_DSD	Numerator: Indication: Routine	268
China	TX_PVLS_DSD	Numerator: Indication: Targeted	0
China	TX_PVLS_DSD	Denominator: Indication: Routine	287
China	TX_PVLS_DSD	Denominator: Indication: Targeted	0
China	TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	1
China	TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	144
China	TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	0
China	TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	123
China	TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1
China	TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	154
China	TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	0
China	TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	132
China	TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	295
China	TX_RET_DSD	Total number of adults and children who	330



		initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	
China	TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
China	TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	156
China	TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
China	TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	138
China	TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
China	TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	177
China	TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and	0



		children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
China	TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	152

Implementing Mechanism Details

Mechanism ID: 16622	Mechanism Name: China CDC COAG
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Chinese Center for Disease Prevention and Control	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Benefiting Country	Benefiting Country Planned Amount
China	0

Total All Funding Sources: 1,300,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 1,300,000		
Managing Country	Funding Source	Funding Amount
China	GAP	150,000
China	GHP-State	1,150,000



Cross-Cutting Budget Attribution(s)

Human Resources for Health	175,000
Key Populations: MSM and TG	610,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs

Budget Code Information

Mechanism ID:	16622		
Mechanism Name:	China CDC COAG		
Prime Partner Name:	Chinese Center for Disease Prevention and Control		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	133,588	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	160,088	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	202,677	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	146,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	166,857	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	361,790	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	5,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	124,000	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
China	KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	20,371
China	KP_PREV_TA	Total estimated number of key population in the catchment area	138,571
China	KP_PREV_TA	By key population type: Men who have sex	20,371



		with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
China	KP_PREV_TA	By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	138,571
China	HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	11,900
China	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	11,900
China	HTC_TST_TA	Sum of Aggregated Age/Sex 15+	11,900
China	HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	11,900
China	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	962
China	HTC_TST_TA	Service Delivery Point (Community): Index testing	11,900

Implementing Mechanism Details

Mechanism ID: 17035	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17084	Mechanism Name: U.S. DoD, Laos
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Benefiting Country	Benefiting Country Planned Amount
Laos	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 20,000		
Total All Funding Sources and Applied Pipeline Amount: 20,000		
Managing Country	Funding Source	Funding Amount
Laos	GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17084		
Mechanism Name:	U.S. DoD, Laos		
Prime Partner Name:	U.S. Department of Defense (Defense)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17092	Mechanism Name: World Health Organization
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Laos	0

Total All Funding Sources:		
75,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 75,000		
Managing Country	Funding Source	Funding Amount
Thailand	GHP-State	75,000

Cross-Cutting Budget Attribution(s)



Key Populations: MSM and TG	20,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs

Budget Code Information

Mechanism ID: 17092			
Mechanism Name: World Health Organization			
Prime Partner Name: World Health Organization			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	5,400	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	24,150	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	33,200	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	12,250	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 17309	Mechanism Name: LINKAGES
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Laos	873,225
Thailand	2,854,296

Total All Funding Sources: 3,727,521		
Applied Pipeline Amount: 1,250,000		
Total All Funding Sources and Applied Pipeline Amount: 4,977,521		
Managing Country	Funding Source	Funding Amount
Laos	GHP-USAID	873,225
Thailand	GHP-USAID	2,854,296

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	3,727,521
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners



Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG

Budget Code Information

Mechanism ID: 17309			
Mechanism Name: LINKAGES			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	631,088	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1,526	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	413,070	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	890,821	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	795,913	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	995,103	0

Implementing Mechanism Indicator Information



OU	Indicator Number	Label	2017
Laos	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	4,020
Laos	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,024
Laos	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,024
Laos	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,024
Laos	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,024
Laos	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	72
Laos	HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,388
Laos	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,388
Laos	HTC_TST_TA	Sum of Aggregated Age/Sex 15+	2,388
Laos	HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	2,388
Laos	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	0
Laos	TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	102
Laos	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	69
Laos	HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting	185



		period, by select cadre	
Thailand	PrEP_NEW_DSD	Number of individuals who have received antiretroviral preexposure	750
Thailand	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	20,140
Thailand	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	15,000
Thailand	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	15,000
Thailand	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	15,000
Thailand	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	15,000
Thailand	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,581
Thailand	TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,900
Thailand	TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,284
Thailand	HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	230

Implementing Mechanism Details

Mechanism ID: 17815	Mechanism Name: Inform Asia: USAID's Health Research Program, Associate Award
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Research Triangle International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



G2G: No	Managing Agency:
---------	------------------

Total All Funding Sources: 0		
Applied Pipeline Amount: 279,500		
Total All Funding Sources and Applied Pipeline Amount: 279,500		
Managing Country	Funding Source	Funding Amount
Thailand	GHP-USAID	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17815		
Mechanism Name:	Inform Asia: USAID's Health Research Program, Associate Award		
Prime Partner Name:	Research Triangle International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17842	Mechanism Name: Quality Improvement Center for Impact (QICI)
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Research Inc./New York State Department of Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Laos	0
Thailand	0

Total All Funding Sources: 50,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 50,000		
Managing Country	Funding Source	Funding Amount
Thailand	GHP-State	50,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17842		
Mechanism Name:	Quality Improvement Center for Impact (QICI)		
Prime Partner Name:	Health Research Inc./New York State Department of Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	50,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 17858	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17859	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17860	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18448	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18450	TBD: Yes
REDACTED	

**Agency Information - Costs of Doing Business
U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied



						Pipeline Amount
Computers/IT Services			15,554	22,981	15,554	38,535
ICASS			15,836	5,804	15,836	21,640
Management Meetings/Professional Development			38,614	886	38,614	39,500
Non-ICASS Administrative Costs			119,639	2,666	119,639	122,305
Staff Program Travel			66,041	5,759	66,041	71,800
USG Staff Salaries and Benefits - Internationally Recruited			233,268	99,201	233,268	332,469
USG Staff Salaries and Benefits - Locally Recruited			236,933	113,593	236,933	350,526
Total	0	0	725,885	250,890	725,885	976,775

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied



						Pipeline Amount
Computers/IT Services		0		1,246	0	1,246
ICASS		0		37,683	0	37,683
Management Meetings/Professional Development		0		785	0	785
Staff Program Travel		0		2,012	0	2,012
USG Staff Salaries and Benefits - Internationally Recruited				0	0	0
USG Staff Salaries and Benefits - Locally Recruited				9,682	0	9,682
Total	0	0	0	51,408	0	51,408

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount



Computers/IT Services	35,000	15,000		0	50,000	50,000
ICASS	100,000	215,000		0	315,000	315,000
Institutional Contractors	102,000	350,000		0	452,000	452,000
Management Meetings/Professional Development	60,000	60,000		0	120,000	120,000
Non-ICASS Administrative Costs	545,000	829,796		0	1,374,796	1,374,796
Staff Program Travel	345,000	155,000		0	500,000	500,000
USG Staff Salaries and Benefits - Internationally Recruited	371,600	983,125		0	1,354,725	1,354,725
USG Staff Salaries and Benefits - Locally Recruited	2,408,275	0		0	2,408,275	2,408,275
Total	3,966,875	2,607,921	0	0	6,574,796	6,574,796